# ᒐᕙᒪᒃᑯᓐᓂ ᐃᓄᖕᓄᑦ ᑐᓴᒐᒃᓴᑦ

## ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ Bivalent ᑲᔾᑎᑕᕐᑲᓕᕐᒥᔪᖅ ᓄᓇᕗᒥᐅᓄᑦ ᐅᑭᐅᓕᖕᓄᑦ 18-ᓂ ᐅᖓᑖᓄᑦᓗ

ᐅᑐᐱᕆ 11, 2022
ᓄᓇᕗᓕᒫᒧᑦ 45 sec

ᐋᓐᓂᐊᕐᑲᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ ᑐᓴᖅᑎᑦᑎᓕᖅᐳᑦ ᓄᕙᒡᔪᐊᓈᒃᑯᑎᒧᑦ ᑲᔾᑎᑦ ᑕᐃᒎᓯᓕᑦ Moderna's bivalent mRNA ᓴᙱᓂᖅᓴᓄᑦ ᑲᐱᔭᐅᓐᓇᖅᓯᙱᔪᖅ ᓄᓇᕗᒥᐅᓕᒫᑦ ᐅᑭᐅᓖᑦ 18-ᓂᒃ ᐅᖓᑖᓂᒡᓗ.

ᑖᓐᓇ bivalent ᑲᐱᔭᐅᔾᔪᑕᐅᓕᖅᐸᑦ ᐊᑕᐅᑦᑎᒃᑰᖅᑕᐅᔪᓐᓇᖅᑐᖅ ᓄᕙᓗᐊᕐᓇᙱᑦᑐᒧᑦ ᑲᐱᔭᐅᔪᕐᑲᖅᑎᓪᓗᒍ.

ᒫᓐᓇᒃᑯᑦ, bivalent–ᒧᑦ ᑲᐱᔭᐅᓲᖑᕗᑦ ᑭᓯᐊᓂ ᐱᖓᓱᓂᒃ ᐊᕐᕕᓂᓕᖕᓄᑦ ᑎᑭᓪᓗᒍ ᑕᖅᑮᑦ ᐊᓂᒍᓚᐅᖅᑎᓪᓗᒋᑦ ᓯᕗᕐᖓᒍᑦ ᑲᐱᔭᐅᑲᑕᓚᐅᖅᑎᓪᓗᒋᑦ ᓴᙱᓂᖅᓴᐅᑉ ᑐᖓᒍᑦ. bivalent-ᒧᑦ ᑲᐱᔭᐅᔪᓐᓇᖅᐳᑦ ᓄᓇᕗᒥᐅᓕᒫᑦ ᐅᑭᐅᖅᑲᖅᑎᒋᔪᑦ 18-ᓂᒃ ᐅᖓᑖᓂᒡᓗ ᑲᐱᔭᐅᓯᒫᓂᒃᑐᑦ ᓯᕗᕐᐊᒍᑦ ᐃᒻᒪᒃ ᒪᕿᐃᖅᓱᕐᓗᑎᒃ ᓄᕙᒡᔪᐊᕐᓇᖅ-19–ᑖᓈᒃᑯᑎᒧᑦ.

ᓄᕙᒡᔪᐊᕐᓇᖅ-19–ᒧᑦ mRNA ᑲᔾᑎᑦ ᐊᑐᐃᓐᓇᐅᓚᐅᖅᑐᑦ ᓱᓕ ᐊᑐᐃᓐᓇᐅᖕᒋᓐᓇᕐᓂᐊᖅᐳᑦ ᓄᓇᕗᒥᐅᓕᒫᓄᑦ ᐊᕐᕕᓂᓕᖕᓂᒃ ᑕᖅᑭᓕᖕᓄᑦ ᐅᖓᑖᓄᑦᓗ ᐊᒻᒪᓗ ᓯᕗᑦᓕᕐᒥᒃ ᑭᖑᑦᓕᐊᓂᒡᓗ ᓴᙱᒃᑎᒋᐊᕈᑎᒧᑦ ᑲᐱᔭᐅᓚᐅᖅᓯᒪᔪᑦ ᐃᓂᒃᓴᓕᐅᕈᓐᓇᕐᓂᐊᖅᑐᑦ ᐋᓐᓂᐊᕕᖕᓄᑦ ᐅᖃᓚᓗᑎᒃ ᐅᕐᑯᒪᐃᓐᓂᕐᓂᐊᕐᕕᖕᓄᑦᓘᓐᓃᑦ.

ᐃᖃᓗᖕᓂ, ᐅᕐᑯᒪᐃᓐᓂᕐᓂᐊᕐᕕᒃ bivalent ᑲᔾᑎᒧᑦ ᐃᓂᒃᓴᓕᐅᖅᓯᒪᔪᑐᐊᑦ ᑲᐱᔭᐅᔪᓐᓇᕐᓂᐊᖅᑐᑦ, ᓯᑎᐱᕆ 19–ᒥ ᐱᒋᐊᕐᓗᓂ, ᓇᒡᒐᔭᒥ ᐅᓪᓗᑐᐃᓐᓇᒧᑦ 9:30–ᒥᑦ 11:30–ᒧᑦ ᐊᒻᒪᓗ 1:00–ᒥᑦ 4:15–ᒧᑦ.

ᐊᐱᖅᑯᑎᒃᓴᖅᑭᕕᑦ ᑲᔾᑎᐅᑉ ᒥᒃᓵᓄᑦ, ᐅᕐᑳᓚᕝᕕᒋᓗᒍ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᑐᑭᓯᒋᐊᕐᕕᖓ ᐊᑭᕐᑲᙱᑦᑐᖅ ᐅᕗᖓ 1-888-975-8601 ᐅᕐᑳᓚᕙᒡᓗᑎᒃ 8:30–ᒥ ᐅᓪᓛᑯᑦ ᐊᒻᒪ 5–ᒥ ᐅᓐᓄᒃᓴᑯᑦ ᐊᑯᓐᓂᐊᓂ. ᑲᓇᖕᓇᒥ ᓇᒡᒐᔭᒥ ᐅᓪᓗᑐᐃᓐᓇᒧᑦ, ᐅᕝᕙᓘᓐᓃᑦ ᐅᕗᖓ ᐃᑭᐊᖅᑭᕕᖕᒧᐊᕐᓗᓯ [ᓄᕙᒡᔪᐊᕐᓇᖅ-19–ᒧᑦ ᑲᐱᔭᐅᓂᖅ.]

ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓐᓂᐊᓕᓈᒃᑯᑏᑦ ᐱᐅᓛᒥᑦ ᓴᐳᔾᔨᓐᓇᖅᑐᑦ ᐱᔪᓐᓃᖅᐸᓪᓕᕐᓗᑎᒃ ᖃᓂᒪᕐᔪᐊᖅᑐᕕᓃᑦ, ᐋᓐᓂᐊᕕᖕᒧᑦ ᐅᓂᒃᓯᒪᓚᐅᖅᑐᑦ ᐊᒻᒪᓗ ᑐᕐᑯᓚᐅᖅᑐᑦ.

###

**ᐱᕙᓪᓕᐊᔪᓂᒃ ᖃᐅᔨᒋᐊᕐᕕᒃᓴᖅ:**

ᑖᓇᕋᐃ ᓴᒧᕕᐅᓪ
ᑐᓴᒐᒃᓴᓕᕆᔨᓄᑦ ᖃᐅᔨᒪᔨᑕᖅ
ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ
867-975-5712
dsommerville1@gov.nu.ca

ᐱᕙᓪᓕᐊᔪᑦ ᑐᓴᒐᒃᓴᙳᖅᑎᑕᐅᔪᑦ ᐱᔭᐅᔪᓐᓇᖃᑦᑕᖅᑐᑦ ᐃᓄᒃᑎᑑᖓᓗᑎᒃ, ᖃᓪᓗᓈᑐᑦ, ᐃᓄᐃᓐᓇᖅᑐᓐ ᐅᐃᕖᑐᓪᓗ ᐅᕙᙱᑦ, *www.gov.nu.ca.*
News releases are available in Inuktitut, English, Inuinnaqtun and French on *www.gov.nu.ca*.
Tuhaqtaghat ittut Inuktitut, Qablunaatitut, Inuinnaqtun Uiviititullu talvani *www.gov.nu.ca*.
Les communiqués de presse sont disponibles en inuktitut, en anglais, en inuinnaqtun et en français au *www.gov.nu.ca*.

ᑐᓴᐅᒪᔪᓕᕆᔨᒃᑯᑦ